Cohort studycited by the Tayebat archivefull text checked A-CHM-17 in-depth review

Chemotherapy in the last months of life did not improve quality of dying

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.

Overview

Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378

In patients still fit, chemotherapy near death was linked to worse quality of the last week.

Does the study support the specific claim? Yes · Methodological quality: moderate

Original publication

Plain-language summary

Study explained simply

What did the researchers want to find out?: Assess end-of-life chemo.
How was the study done?: Prospective cohort.
How many people, animals or samples were studied?: 312.
What was actually found?: No survival or QoD benefit.
How large was the observed effect?: OR 0.35 (ECOG 1).
What do the results mean in everyday life?: Discuss goals of care near end of life.
What are the study's limitations?: Not randomised; chemotherapy users were younger and fitter; only patients who died were analysed; no dose data; caregiver-rated outcome.
What does it say about Elawady's specific claim?: Supports for end-stage only.
Do the results apply to Germany and Europe?: Moderate.
What can explicitly not be concluded from this study?: That chemotherapy is harmful in curative, adjuvant or first-line settings; that chemotherapy never prolongs life in advanced cancer.

Scientific in-depth review

1. Full reference

Authors: Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK
Journal: JAMA Oncol
Year: 2015
Identifier: PMID 26203912 DOI 10.1001/jamaoncol.2015.2378 · PMC4828728
Verification: verified – PubMed E-utilities efetch, 2026-10-25
Retracted: no
Corrections: none
Extent checked: full text
Conflicts of interest and funding: Funding: NIMH MH63892, NCI CA106370, NIMHD MD007652, Weill Cornell Medical College grant, VA HSR&D Career Development Award; funders had no role. COI: Dr LeBlanc consulted for Helsinn Therapeutics, Epi-Q and Boehringer Ingelheim; Dr Neugut consulted for Pfizer, Otsuka, United Biosource Corporation and EHE Intl; no other disclosures.

2. Research question

Association of chemotherapy near death with quality of life at death by performance status.

3. Study design and population

Study design: Cohort study – Multi-institutional prospective cohort (Coping with Cancer study); analysis restricted to patients who died during observation
Population: Adults (>=20 y) with end-stage cancer (distant metastases, refractory to >=1 chemotherapy line, physician-estimated life expectancy <=6 months) with an informal caregiver; ECOG 0: 2.9%, 1: 39.1%, 2: 37.2%, 3: 18.6%, 4: 2.2%
Country: USA (6 clinics)
Period: 2002-2008
Sample size: 312 decedents analysed (of 939 eligible, 661 participating [70.4%], 384 died; 33 excluded for clinical-trial participation, 39 for missing data); 158 (50.6%) on chemotherapy at baseline
Inclusion and exclusion criteria: Included: distant metastases, disease refractory to >=1 line of chemotherapy, life expectancy <=6 months, age >=20, participating caregiver, adequate stamina. Excluded: serious cognitive impairment, no fluency in English/Spanish; for this analysis also clinical-trial participants and missing data.

4. Methods and endpoints

Exposure / intervention: Chemotherapy use at baseline (chart review), median 3.8 months before death; dose, duration, prior lines and chemotherapy after baseline not recorded
Comparator: No chemotherapy
Endpoints: Quality of life near death (QOD): caregiver-rated composite of psychological distress, physical distress and overall QOL in the final week (0-10; Cronbach alpha .76), dichotomised at the median (>=7 = higher); survival
Statistical methods: Cox model for survival adjusted for site and ECOG; logistic regression with chemotherapy x ECOG interaction, then ECOG-stratified logistic models (ORs), log-binomial risk ratios and t-tests; covariates included only if associated with QOD at P<.05 (none were), so stratum ORs are unadjusted; exploratory mediation by ICU care.

5. Actual results

Results: Survival not associated with chemotherapy (adjusted HR 0.85, 95% CI 0.65-1.11). ECOG modified the chemotherapy-QOD association (interaction OR 1.95, 1.13-3.35). ECOG 1: higher QOD in 31/71 (43.7%) with vs 35/51 (68.6%) without chemotherapy; OR 0.35 (0.17-0.75), RR 0.64 (0.46-0.88); mean QOD 6.0 vs 7.0 (difference -1.0, -1.9 to -0.1); remained significant after adjustment for ICU care. ECOG 2: OR 1.06 (0.51-2.21); ECOG 3: OR 1.34 (0.46-3.89). Chemotherapy users were younger, more educated, had lower comorbidity, better ECOG and were mostly treated at academic centres (AOR 17.1 vs community clinic).
Absolute risks: ECOG 1: proportion with higher quality of death 43.7% (chemotherapy) vs 68.6% (no chemotherapy); ECOG 2: 49.1% vs 47.5%; ECOG 3: 54.5% vs 47.2%.
Authors' conclusion: Chemotherapy use among patients with chemotherapy-refractory metastatic cancer is of questionable benefit to QOL in the final week; it did not improve QOD at any performance status and worsened it in patients with good performance status; ASCO guidelines may need revision. The study was neither designed nor powered for survival; lack of survival benefit should not be read as proof that none exists.

6. Strengths

Prospective, multi-site cohort with patients followed until death
Chemotherapy use documented from charts in real time
Validated caregiver-rated QOD measure
Prespecified hypothesis of effect modification by performance status
Comprehensive baseline characterisation (comorbidity, ECOG)

7. Weaknesses

Non-randomised; strong confounding by indication (chemotherapy users younger, fitter, academic centres) and no adjustment in stratum-specific models
Only decedents analysed (312 of 661 participants); patients who lived longer, possibly due to treatment, are excluded
No data on chemotherapy dose, duration, prior lines or changes after baseline
QOD rated by caregivers after death; dichotomised at median; no minimal important difference
Small strata (ECOG 1 n=122, ECOG 3 n=58); wide CIs; post-hoc stratification after interaction test
Not powered for survival (authors)

8. Risk of bias

Orienting tool: ROBINS-E
Type of assessment: structured assessment based on the full text by a single reviewer (no formal double review)
Full formal assessment: no
Overall risk of bias: high
Rationale: Unchanged overall judgement (high); full text confirms no covariate adjustment in stratified analyses and restriction to decedents. Single-reviewer structured judgement from the full text; a formal assessment requires two independent reviewers and a protocol.

8. Risk of bias
Domain	Judgement	Rationale
Confounding	high	Chemotherapy users differed markedly (age, education, comorbidity, ECOG, site, cancer type); covariates were selected only by association with the outcome and none were adjusted for in the ECOG-stratified ORs.
Measurement of exposure	some concerns	Binary chemotherapy status at a single time point; no dose, duration or subsequent treatment data.
Selection of participants	high	Analysis conditioned on death during observation and excluded clinical-trial participants; survivors (58.1% died) differed in characteristics.
Post-exposure interventions	some concerns	Chemotherapy starts/stops after baseline unknown; ICU care explored as mediator.
Missing data	low	39 excluded for missing data did not differ on measured characteristics.
Measurement of outcome	some concerns	Validated but proxy (caregiver) retrospective rating a median 2.4 weeks after death; caregivers aware of treatment.
Selection of reported result	some concerns	Hypothesis stated a priori, but primary continuous measure dichotomised at the median and results emphasised in one stratum after an interaction test.

Full-text review (25 October 2026): Added participant flow (939 eligible, 661 participants, 312 decedents analysed), exact inclusion criteria, survival HR 0.85 (0.65-1.11), interaction OR 1.95, absolute proportions with higher QOD by stratum (ECOG 1: 43.7% vs 68.6%), lack of covariate adjustment in stratified ORs, restriction to decedents, authors' caveat on survival, full funding and consultant COIs. ROBINS-E overall unchanged (high).

9. Assessment of the statistical interpretation

Applies only to chemotherapy-refractory metastatic disease near death. The ECOG-1 association (OR 0.35) is unadjusted and based on 122 patients; ECOG 2-3 estimates are imprecise and compatible with benefit or harm. No survival difference (HR 0.85, 0.65-1.11), but the study was not powered for survival.

10. Relevance to the specific claim

Supports critique of end-of-life over-treatment.

11. Independent contrary findings

I-CHM-01/02 for curative settings.

12. Transferability to Germany and Europe

Moderate.

13. Overall methodological judgement

Valid evidence of questionable benefit of chemotherapy for refractory metastatic cancer near death, with high risk of confounding and selection bias; cannot be generalised to curative, adjuvant or first-line palliative treatment.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	moderate
Risk of bias	high
Precision of results	low
Directness	direct
Reproducibility	unknown
Consistency with the overall evidence	unknown
Regional transferability	moderate
Adequacy of the interpretation (by the archive)	essentially correct but incomplete

14. Open questions

Randomised or propensity-based evaluation of late-line chemotherapy in refractory disease; QOL over months rather than the final week; modern targeted and immunotherapy agents.

15. Linked fact checks

At the end of life, chemotherapy often does not help, and early palliative care improves quality of life and even survival (Temel 2010). – Studies supporting the claim

Use by the Tayebat archive

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study: Listed in bibliography (end-of-life chemotherapy).
A. What was actually studied?: Chemo near death.
B. What did the authors find?: No QoD benefit; harm in good-PS patients.
C. What conclusions do the authors themselves draw?: Chemo near death not beneficial.
D. What does the archive derive from it?: Over-treatment at end of life.
E. Is this derivation scientifically justified?: Yes, if restricted to chemotherapy-refractory metastatic cancer in the last months of life. The full text shows the main association is unadjusted, the analysis included only patients who died, and the authors state the lack of survival benefit should not be taken as proof that none exists; it cannot be generalised to curative or adjuvant treatment.
Adequacy of the interpretation (by the archive): essentially correct but incomplete